Press Releases Takeda Pharmaceutical Company Limited London S.E.

Equities

0A87

US8740602052

Market Closed - London S.E. Other stock markets 11:28:45 2024-06-18 am EDT			After market 02:45:13 pm
12.74 ^USD	-2.52%		12.6	-1.06%

Jun. 18	Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	MT
Jun. 18	Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	Jun. 19	AQ
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat	Jun. 18	AQ
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting	Jun. 18	BU
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K	Jun. 17	PU
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	Jun. 17	BU
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	Jun. 14	BU
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts	Jun. 11	BU
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K	Jun. 11	PU
TAKEDA PHARMACEUTICAL : Form 6 K	Jun. 10	PU
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K	Jun. 07	PU
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan	Jun. 04	AQ
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo	Jun. 03	BU
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	May. 31	BU
Takeda Pharmaceutical : Other items which are provided electronically	May. 29	PU
TAKEDA PHARMACEUTICAL : Form 6-K	May. 21	PU
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection	May. 16	AQ
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting	May. 14	BU
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease	May. 13	BU
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement	May. 10	AQ
Takeda Pharmaceutical, Announces full-year 2023 results and outlook for 2024 Emphasizes commitment to late-stage pipeline development and core operating margin improvement	May. 10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Takeda Pharmaceutical Company Limited London S.E.

Equities

0A87

US8740602052

Press Releases

Filters